Perspectives - Page 20

Go-To-Market (GTM): Market-Shaping Launch Commercialization Planning for a Gene Therapy Asset in a Congenital Rare Disease Therapy Area

Shaping the market (as part of a wider go-to-market strategy) to fully appreciate the value that a gene therapy asset can bring, and working across a matrixed organization to develop, implement, and track a launch commercialization plan to address GTM market-shaping objectives (T-24 months to launch)

Case Study Sep 20, 2021

Women in Biotech Progress – Yet Challenges Remain, Update on Female Innovators in Biotech

View Sep 6, 2021

Heterogeneity & Generalizability: The Core Difficulties in Estimating the Effectiveness of Tumour-Agnostic Drugs in Practice

Whitepaper Sep 3, 2021

Competitor Scenario Planning and Mitigation Strategy Development for Launch Commercialization

Case Study Aug 26, 2021

Are We Nearing the Plateau of Productivity for In-Vivo Therapeutic Gene Editing?

View Aug 24, 2021

Investment in Therapeutic Innovations for Genetic Disorders – A Brainstorm for the Overall Neurology and Musculoskeletal Sectors

On-Demand Webinar Aug 19, 2021

Women Leaders in Biotechnology Inspire From Kendall Square

View Aug 18, 2021

Novel Cell-Type Therapeutic Platforms in Oncology: If You’ve Seen One, You’ve Seen… One

On-Demand Webinar Aug 11, 2021

Understanding the Payer Mindset Throughout the Brand Journey

Whitepaper Aug 9, 2021

Opinion Leader Identification and Engagement Planning

Case Study Aug 8, 2021

An Introduction to Planning for HTA for Tumour-Agnostic Cancer Drugs

Therapies designed to target cancers with specific molecular signatures have reshaped the landscape of oncological drug development.¹ The advent of tumour-agnostic therapies represents both a major opportunity for patients to receive therapies targeted to their specific disease on a molecular level and an important step towards discovering biomarkers of response.

Whitepaper Aug 4, 2021

Precision vs Imprecision Oncology

View Jul 29, 2021

Medical Affairs Unscripted | Executing Launch: Develop, Visualize, and Communicate with John Walsh, MD

Podcast Jul 28, 2021

Developing the First EMEA Cross-Functional Strategic Plan for an Autologous CAR T-Cell Therapy Asset with a Newly-Formed Launch Commercialization Team (T-30 months)

Case Study Jul 19, 2021

Pharma Launch Team Ways of Working – Top Tips

View Jul 13, 2021

Silver Lining to Approval of Aducanumab?

The accelerated and broad label approval of Biogen’s Alzheimer's Disease (AD) drug aducanumab (Aduhelm) is controversial (to say the least) on many fronts.

View Jul 8, 2021